logo-loader

Cellmid receives patent for midkine treatment in Europe

Published: 13:30 07 Feb 2017 AEDT

Patent
The MK alopecia patent complements other members already granted

Cellmid's (ASX:CDY) patent for midkine (MK) treatment of alopecia has been allowed by the European Patent Office.

The importance of the patent is that it supplied comprehensive protection over midkine for the prevention or reversal of hair loss.

The European midkine alopecia patent will expire in February 2031.


Patents

A week ago Cellmid was issued a notice of allowance for a patent entitled “Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth” by the U.S. Patent and Trademark Office.

The MK alopecia patent will expire in February 2031.

The MK alopecia patent complements other members already granted in the patent family in Japan, Australia and the U.K. providing broad geographical protection over the use of the MK protein for the treatment of a number of conditions resulting in hair loss.

The alopecia patent also adds to the key patent families that ensure the company’s dominant intellectual property position over the treatment of inflammatory, ischaemic and autoimmune diseases, cancer and bone disorders by targeting or using MK.

Cellmid’s total patent portfolio currently comprises 75 patents and applications in 16 patent families.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

13 hours, 29 minutes ago